Rhythm Pharmaceuticals (RYTM) Stock: Buy, Sell, or Hold?
RYTM - Rhythm Pharmaceuticals, Inc. Common Stock
$104.71
2.51 (2.46%)
▲
5d:
-0.17%
30d:
-10.96%
90d:
+19.45%
BUY
MODERATE Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When RYTM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RYTM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RYTM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RYTM is currently trading at $104.71, which is considered oversold relative to its 30-day fair value range of $104.83 to $114.95.
Technical Outlook: Technically, RYTM is in a strong uptrend. Immediate support is located at $99.41, while resistance sits at $114.75.
Market Sentiment: RYTM scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $140.19 (+33.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RYTM is in a strong uptrend. Immediate support is located at $99.41, while resistance sits at $114.75.
Market Sentiment: RYTM scores 66/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $140.19 (+33.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$104.83 -
$114.95
Company Quality Score
62/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
95.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (66/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 33.9% below Wall St target ($140.19)
- BULLISH: Bottoming setup score 66/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$104.83 -
$114.95
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$7.27
(6.9%)
Support & Resistance Levels
Support Level
$99.41
Resistance Level
$114.75
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-170.45
Wall Street Target
$140.19
(+33.9%)
Revenue Growth (YoY)
46.9%
Profit Margin
-85.6%
Share & Embed Analysis
Last updated: September 12, 2026 3:54 AM ET
Data refreshes hourly during market hours. Next update: 4:54 AM
Data refreshes hourly during market hours. Next update: 4:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RYTM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
Advanced RYTM Option Strategies
Professional options setups generated by AI based on today's RYTM price and gamma walls.
